Everything Old is New Again: FDA Revises its 2014 Rare Pediatric Disease Priority Review...

[cafead]

via Offering priority review vouchers to sponsors that develop new drugs for children with rare diseases is an important incentive program that has wide support. This week, FDA published a revised draft guidance of the original November 2014 draft guidance titled, “Rare Pediatric Disease Priority Review Vouchers, Guidance for Industry” (hereinafter “revised guidance”).

article source